- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | 2026: The road ahead with Lumos Diagnostics | 5 | Stockhead | ||
| Mi | LUMOS DIAGNOSTICS HOLDINGS LIMITED: Investor Webinar Invitation-Reducing Diagnostic Uncertainty | 1 | ASX | ||
| LUMOS DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 18.12.25 | LUMOS DIAGNOSTICS HOLDINGS LIMITED: Lumos Secures Distribution for FebriDx in Baltic Region | 1 | ASX | ||
| 08.12.25 | Dr Boreham's Crucible: Lumos awaits the FDA's billion-dollar verdict | 1 | Stockhead | ||
| 28.11.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 28.11.2025 | 515 | Xetra Newsboard | The following instruments on XETRA do have their first trading 28.11.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 28.11.2025
Aktien
1 US87507T1016 Tamboran Resources Corp.
2... ► Artikel lesen | |
| 21.11.25 | Lumos Diagnostics Secures Full US Medicare Reimbursement Recognition for FebriDx Test | 1 | smallcaps.com.au | ||
| 21.11.25 | LUMOS DIAGNOSTICS HOLDINGS LIMITED: Section 708A Cleansing Statement | 11 | ASX | ||
| 21.11.25 | LUMOS DIAGNOSTICS HOLDINGS LIMITED: Application for quotation of securities - LDX | 1 | ASX | ||
| 21.11.25 | LUMOS DIAGNOSTICS HOLDINGS LIMITED: Lumos Secures 100% US Medicare Reimbursement for FebriDx | 1 | ASX | ||
| 20.11.25 | Lumos teams with AcuityMD to boost US rollout of FebriDx rapid diagnostic test | 1 | Stockhead | ||
| 19.11.25 | LUMOS DIAGNOSTICS HOLDINGS LIMITED: Lumos Enters Strategic Collaboration with AcuityMD | - | ASX | ||
| 17.11.25 | Bacterial or viral? Lumos moves to close a widening diagnostic gap as respiratory cases rise | 1 | Stockhead | ||
| 12.11.25 | LUMOS DIAGNOSTICS HOLDINGS LIMITED: Notification regarding unquoted securities - LDX | - | ASX | ||
| 31.10.25 | LUMOS DIAGNOSTICS HOLDINGS LIMITED: Application for quotation of securities - LDX | - | ASX | ||
| 31.10.25 | LUMOS DIAGNOSTICS HOLDINGS LIMITED: Notification regarding unquoted securities - LDX | 2 | ASX | ||
| 28.10.25 | LUMOS DIAGNOSTICS HOLDINGS LIMITED: New Constitution | - | ASX | ||
| 24.10.25 | LUMOS DIAGNOSTICS HOLDINGS LIMITED: Results of Annual General Meeting | - | ASX | ||
| 24.10.25 | ASX Quarterly Health Wrap: Lumos lands US$317m deal as ReNerve and Vitrafy hit key milestones | 1 | Stockhead | ||
| 23.10.25 | LUMOS DIAGNOSTICS HOLDINGS LIMITED: 2025 AGM Presentation | - | ASX | ||
| 23.10.25 | LUMOS DIAGNOSTICS HOLDINGS LIMITED: AGM Chair Address | - | ASX |
1 2 3 4 Weiter >>
69 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 46,530 | +0,48 % | DEUTSCHE BANK RESEARCH stuft Siemens Healthineers auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Siemens Healthineers auf "Hold" mit einem Kursziel von 46 Euro belassen. Er rechne damit, dass der Start in das neue Geschäftsjahr... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 39,010 | -0,43 % | EILMELDUNG: Fresenius Medical Care-Aktie bricht ein - Panik greift um sich! | ||
| FRESENIUS | 49,750 | +1,59 % | Amneal Pharma, MAbxience: FDA Approves Denosumab Biosimilars Referencing Amgen's Prolia And XGEVA | THOUSAND OAKS (dpa-AFX) - Amneal Pharmaceuticals, Inc. (AMRX) announced late Monday that the U.S. Food and Drug Administration has approved the Biologics Licensing Applications or BLAs for Boncresa... ► Artikel lesen | |
| LUMEXA IMAGING | 17,730 | +2,37 % | Lumexa Imaging Draws Bullish Analyst Calls On Heels Of IPO | ||
| ALIGNMENT HEALTHCARE | 20,950 | 0,00 % | Where Alignment Healthcare Stands With Analysts | ||
| BRIGHTSPRING HEALTH SERVICES | 39,080 | 0,00 % | S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P SmallCap 600 | NEW YORK, Oct. 14, 2025 /PRNewswire/ -- BrightSpring Health Services Inc. (NASD: BTSG) will replace Veritex Holdings Inc. (NASD: VBTX) in the S&P SmallCap 600 effective... ► Artikel lesen | |
| BETA BIONICS | 31,990 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 34,480 | 0,00 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| HEARTFLOW | 33,470 | 0,00 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 41,680 | -2,25 % | EQS-PVR: Carl Zeiss Meditec AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Carl Zeiss Meditec AG
Carl Zeiss Meditec AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the... ► Artikel lesen | |
| PROGYNY | 27,440 | 0,00 % | Progyny-Aktie: Truist Securities stuft auf 'Kaufen' hoch und verweist auf verbesserte Aussichten | ||
| ECKERT & ZIEGLER | 15,410 | -2,41 % | Eckert & Ziegler - Kurzbericht zur Aktienentwicklung | ||
| MIMEDX | 6,310 | -2,02 % | MiMedx Group, Inc: MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit-Wound Gel | MARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced it has entered into an exclusive agreement with Regen Lab USA LLC to... ► Artikel lesen | |
| NEUROPACE | 16,960 | +0,89 % | BDMD: Baird Medical Appoints Mark Saxton as U.S. CEO; Taps Veteran from NeuroPace, Smith + Nephew, and Covidien to Lead Commercial Expansion | NEW YORK, Dec. 3, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive... ► Artikel lesen | |
| BILLIONTOONE | 87,59 | 0,00 % | BillionToOne, Inc.: BillionToOne Reports Third Quarter 2025 Results | MENLO PARK, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are... ► Artikel lesen |
Das Unternehmen LUMOS DIAGNOSTICS HOLDINGS LIMITED kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,95 % bei einem Aktienkurs von 0,156 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LUMOS DIAGNOSTICS HOLDINGS LIMITED finden Sie auf Wallstreet Online.